
Decision of the Athletics Integrity Unit in the Case of Ms Yelena Kotulskaya (the "Athlete")

Factual Background

1. On 16 July 2016 and 9 December 2016, Prof. Richard McLaren published two reports into allegations of a systemic doping scheme in Russia (the First¹ and Second McLaren Reports², together the "**McLaren Reports**"). In the McLaren Reports, Prof. McLaren made findings with respect to the scheme and concluded that Russian athletes had been protected over the course of years. In other words, a vast number of positive samples had been officially reported as negative. The three main counter-detection methodologies which were used in Russia, at least between 2011 and 2015, were the so-called (i) Disappearing Positives Methodology ("**DPM**")³, (ii) the Sample Swapping Methodology⁴ and (iii) Washout Testing⁵.
2. On 30 October 2017, the World Anti-Doping Agency ("**WADA**") Intelligence & Investigations Department ("**WADA I&I**") secured from a whistleblower a copy of the Laboratory Information Management System ("**LIMS**") data of the Moscow Laboratory for the years 2011 to August 2015 (the "**2015 LIMS**").
3. The LIMS is a system that allows a laboratory to manage a sample through the analytical process and the resultant analytical data. Conceptually, the LIMS is a warehouse of multiple databases organized by year. The most relevant anti-doping data within the LIMS are those

¹ <https://www.wada-ama.org/en/resources/doping-control-process/mclaren-independent-investigation-report-part-i>

² <https://www.wada-ama.org/en/media/news/2016-12/wada-publishes-independent-mclaren-investigation-report-part-ii>

³ Where the initial testing procedure of a sample revealed a Presumptive Adverse Analytical Finding the athlete would be identified, and the Russian Ministry of Sport would decide either to "SAVE" or to "QUARANTINE" the athlete in question. The instruction would typically be sent by email; however, at times, "SAVE" instructions were also known to be given by other means than email, eg. orally or by text message and certain athletes were automatically protected without the need for any instruction. If the instruction was "SAVE", the analysis of the sample would stop and the Moscow Laboratory would report the sample as "negative" in ADAMS.

⁴ The Sample Swapping Methodology involved the replacing of "dirty" urine with "clean" urine by removing and replacing the cap on sealed B sample bottles. This was facilitated by the establishment and maintenance of a "Clean Urine Bank" at the Moscow Laboratory.

⁵ The Washout Testing was developed in order to determine whether the athletes on a doping program were likely to test positive. The results of the Washout Testing were at times recorded in documents, such as the London Washout Schedules in the lead-up to the 2012 London Olympic Games or the Moscow Washout Schedule in the lead-up to the 2013 IAAF World Championships. Even when the samples screened positive, they were automatically reported as negative in ADAMS. See page 23 and 72 of the Second McLaren Report.

related to sample reception, analysis, and the actions of users within the system. This pertinent data is housed in key tables including: “bags”, “samples”, “screening”, “found” (or “scr_results” prior to 2013), “confirmation”, “MS_data” (or “Pro_4” prior to 2013) and “pdf”.

4. Subsequently, as part of the reinstatement process of the Russian Anti-Doping Agency (“**RUSADA**”), WADA required that inter alia authentic analytical data from the Moscow Laboratory for the years 2012 to 2015 be provided. Access to the Moscow Laboratory was therefore given to a team of WADA-selected experts, who were allowed to remove data from the Moscow Laboratory, including another copy of the LIMS data for the relevant years (the “**2019 LIMS**”) as well as the underlying analytical PDFs and raw data of the analyses reported in the LIMS (the “**Analytical Data**”). The analytical PDFs are automatically generated from the instruments and contain the chromatograms, which demonstrate whether a substance is present or not in a given sample.
5. Further investigations were conducted by WADA I&I in collaboration with forensic experts from the University of Lausanne on the data retrieved from the Moscow Laboratory and evidence of manipulation of the 2019 LIMS was uncovered, in particular, to remove positive findings contained in the LIMS. On that basis, WADA I&I concluded that the 2015 LIMS was reliable (and the 2019 LIMS was not). WADA I&I also identified evidence of deletions/alterations of Analytical Data to remove evidence of positive findings prior to WADA’s retrieval mission in January 2019.⁶
6. In the present case, in addition to the McLaren Reports evidence, the 2015 LIMS data and the Analytical Data show that three of the Athlete’s samples contained a prohibited substance and were not reported as positive as part of the Russian manipulation scheme. More particularly:

Sample 2780822

- 6.1. On 14 June 2013, the Athlete was subject to an out-of-competition urine doping control. The 2015 LIMS indicates that ostarine was found in this sample.
- 6.2. Ostarine is a selective androgen receptor modulator prohibited under S1.2 of the 2013 WADA Prohibited List.
- 6.3. The sample was reported negative by the Moscow laboratory.

⁶ See in particular CAS 2020/O/6689, para. 614: “*The Panel finds that, prior to the Moscow Data being retrieved by WADA in January 2019, and during its retrieval, it was subjected to deliberate, sophisticated and brazen alterations, amendments and deletions. Those alterations, amendments and deletions were intentionally carried out in order to remove or obfuscate evidence of improper activities carried out by the Moscow Laboratory as identified in the McLaren Reports or to interfere with WADA’s analysis of the Moscow Data*”.

Sample 2808100

- 6.4. On 23 July 2013, the Athlete was subject to an out-of-competition urine doping control. The 2015 LIMS indicates that salmeterol and fluticasone propionate were found in this sample.
- 6.5. Salmeterol is prohibited under S3 (Beta-2 Agonists) of the 2013 WADA Prohibited List and fluticasone propionate is prohibited in-competition under S9 (Glucocorticoids) of the 2013 WADA Prohibited List.
- 6.6. On 25 July 2013, Liaison Person Aleksey Velikodny sent an email to Dr. Rodchenkov and Dr. Sobolevsky (of the Moscow laboratory) with the following content (EDPO141):

SAVE

ATHLETICS 2808100 – Kotulskaya Elena, F, athletics, Russia's Championship | 11801, RU
Moscow
salmeterol

- 6.7. The sample was reported negative by the Moscow laboratory.

Sample 2807678

- 6.8. On 16 August 2013, the Athlete was subject to an out-of-competition urine doping control. The 2015 LIMS indicates that salmeterol and fluticasone propionate were found in this sample.
- 6.9. Salmeterol is prohibited under S3 (Beta-2 Agonists) of the 2013 WADA Prohibited List and fluticasone propionate is prohibited in-competition under S9 (Glucocorticoids) of the 2013 WADA Prohibited List.
- 6.10. The sample was reported negative by the Moscow laboratory.

Moscow Washout Schedule

- 6.11. The Athlete's name features in the Moscow Washout Schedules against two samples with the following text (see eg. EDPO028):

	1	2
Katulskaya 17/07		T/E = 3.5, prohormones, salmeterol
Katulskaya 23/07	Russia	salmeterol

- 6.12. The AIU considers the second sample on the Moscow Washout Schedule to correspond to sample 2808100 mentioned above.

Procedural Background

7. On 8 June 2023, the Athlete was notified by the Athletics Integrity Unit ("AIU") of a potential Anti-Doping Rule Violation ("ADRV") under the IAAF 2012-2013 Competition Rules and of her

right to provide a written explanation or to admit the potential ADRV by 20 June 2023 at the latest (the “**Notification of a Potential Anti-Doping Rule Violation**”)⁷.

8. The Athlete failed to respond to the Notification of a Potential Anti-Doping Rule Violation within the given deadline or at all.
9. By letter dated 6 December 2024, the AIU granted the Athlete a final opportunity *(i)* to admit the violation and accept the consequences outlined in that letter by 26 December 2024 or *(ii)* to request a hearing by 20 December 2024 (the “**Notification of Asserted Anti-Doping Rule Violation**”).
10. The Athlete did not respond to the Notification of Asserted Anti-Doping Rule Violation within the given deadline or at all.

Reasoned Decision

A. Applicable Rules

11. Pursuant to Rule 1.7.2(b) of the 2025 World Athletics Anti-Doping Rules (“**2025 ADR**”), anti-doping rule violations committed prior to 1 January 2025 shall be governed by the substantive Anti-Doping Rules in effect at the time the alleged anti-doping rule violation occurred and, with respect to procedural matters, by the 2025 ADR (unless by the Effective Date, the case has already been referred to a hearing body in accordance with Rule 38 of the 2016-2017 IAAF Competition Rules).
12. As the Athlete’s anti-doping rule violations occurred between June and August 2013, they are governed by the rules in force at the time of their commission, viz. the 2012-2013 IAAF Competition Rules (the “**IAAF Competition Rules**”).

B. Anti-Doping Rule Violation

13. Per Rule 32.2(b) of the IAAF Competition Rules, the Use of Prohibited Substances constitutes an anti-doping rule violation. The provision adds the following:

“(i) it is each Athlete’s personal duty to ensure that no Prohibited Substance enters his body. Accordingly, it is not necessary that intent, fault, negligence or knowing Use on the Athlete’s part be demonstrated in order to establish an anti-doping rule violation for Use of a Prohibited Substance or a Prohibited Method.

“(ii) the success or failure of the Use or Attempted Use of a Prohibited Substance or Prohibited Method is not material. It is sufficient that the Prohibited Substance or Prohibited Method was Used, or Attempted to be Used, for an antidoping rule violation to be committed.”

⁷ On 20 June 2023, RUSAF confirmed that the Athlete had been notified (and the letter forwarded to her via WhatsApp).

14. Use within the meaning of Rule 32.2(b) of the IAAF Competition Rules can be established “*by any reliable means, including but not limited to admissions, evidence of third Persons, witness statements, experts reports, documentary evidence, conclusions drawn from longitudinal profiling and other analytical information*” (Rule 33.3 of the IAAF Competition Rules).
15. In the present case, in addition to the McLaren Reports evidence, the 2015 LIMS data and underlying Analytical Data show that ostarine, salmeterol and fluticasone propionate were detected in samples collected from the Athlete between June and August 2013. This clear and reliable evidence shows that the Athlete used Prohibited Substances in 2013 under Rule 32.2(b) of the IAAF Competition Rules.
16. In addition, the AIU notes that, when confronted with the anti-doping rule violation, the Athlete did not provide any explanation for it. In addition, having failed to request a hearing, the Athlete is deemed to have accepted the anti-doping rule violation.
17. In view of the above, it is clear that the Athlete committed an anti-doping rule violation under Rule 32.2(b) of the IAAF Competition Rules.

C. Applicable Consequences

1) *Period of Ineligibility*

18. Per Rule 40.7(d) of the IAAF Competition Rules, “[f]or the purposes of imposing sanctions under Rule 40.7, an anti-doping rule violation will only be considered a second violation if it can be established that the Athlete or other Person committed the second anti-doping rule violation after the Athlete or other Person received notice pursuant to Rule 37 (Results Management) or after reasonable efforts were made to give notice of the first anti-doping rule violation; if this cannot be established, the violations shall be considered together as one single first violation and the sanction imposed shall be based on the violation that carries the more severe sanction; however, the occurrence of multiple violations may be considered as a factor in determining aggravating circumstances (Rule 40.6).”
19. In the present case, the anti-doping rule violations relate to samples collected between June and August 2013 and were notified simultaneously to the Athlete. Therefore, they should be treated under the applicable rules as a single violation. In this respect, Rule 40.2 of the IAAF Competition Rules sets out that “[t]he period of Ineligibility imposed for a violation of [...] 32.2(b) (Use or Attempted Use of a Prohibited Substances or Prohibited Method) [...], unless the conditions for eliminating or reducing the period of Ineligibility as provided in Rules 40.4 and 40.5, or the conditions for increasing the period of Ineligibility as provided in Rule 40.6 are met, shall be as follows: First Violation: Two (2) years’ Ineligibility.”
20. Pursuant to Rule 40.6 of the IAAF Competition Rules, if it is established that “*aggravating circumstances are present which justify the imposition of a period of Ineligibility greater than the standard sanction, then the period of Ineligibility otherwise applicable shall be increased up to a maximum of four (4) years unless the Athlete or other Person can prove to the comfortable satisfaction of the hearing panel that he did not knowingly commit the anti-doping rule violation.*”

21. Examples of aggravating circumstances include the following per Rule 40.6(a) of the IAAF Competition Rules: *“the Athlete or other Person committed the antidoping rule violation as part of a doping plan or scheme, either individually or involving a conspiracy or common enterprise to commit anti-doping rule violations; the Athlete or other Person used or possessed multiple Prohibited Substances or Prohibited Methods or used or possessed a Prohibited Substance or Prohibited Method on multiple occasions; a normal individual would be likely to enjoy performance-enhancing effects of the anti-doping rule violation(s) beyond the otherwise applicable period of Ineligibility; the Athlete or other Person engaged in deceptive or obstructing conduct to avoid the detection or adjudication of an anti-doping rule violation.”*
22. In the present case, the fact that the ADRVs were committed as part of the most sophisticated doping and anti-detection scheme in history, aimed at ensuring that Russian athletes who were using prohibited substances would escape any violation or sanction, clearly constitutes an aggravating circumstance. In addition, the Athlete committed multiple violations, involving multiple prohibited substances.
23. In view of the above, it is clear that aggravating circumstances are present with respect to the Athlete’s present anti-doping rule violation and that the maximum sanction of four years of Ineligibility under Rule 40.6 of the IAAF Competition Rules is therefore warranted and proportionate to the serious offences committed.

2) Disqualification

24. Per Rule 40.8 of the IAAF Competition Rules, *“[i]n addition to the automatic disqualification of the results in the Competition which produced the positive sample under Rules 39 and 40, all other competitive results obtained from the date the positive Sample was collected (whether In-Competition or Out-of-Competition) or other anti-doping rule violation occurred through to the commencement of any Provisional Suspension or Ineligibility period shall be Disqualified with all of the resulting Consequences for the Athlete including the forfeiture of any titles, awards, medals, points and prize and appearance money.”*
25. In the present case, the evidence of the Athlete’s anti-doping rule violations was on 14 June, 23 July and 16 August 2013. As a result, per Rule 40.8 of the IAAF Competition Rules, all results obtained by the Athlete from 14 June 2013 until the date of this decision must be disqualified, with all resulting consequences, including forfeiture of any titles, awards, medals, points, and prize and appearance money. The AIU sees no reason of fairness justifying otherwise given the severity of the violations committed by the Athlete. In addition, the Athlete has not even sought to argue that the fairness exception should apply.

D. Dispositive

26. In view of all the above, the following decision is hereby rendered (with binding effect on all Signatories to the World Anti-Doping Code, in all sports and countries as per Code Article 15):
 - 26.1. Ms Kotulskaya is found to have committed an anti-doping rule violation under Rule 32.2(b) of the IAAF Competition Rules;

- 26.2. Ms Kotulskaya is imposed a period of Ineligibility of four (4) years starting from the date of this decision;
- 26.3. All competitive results obtained by Ms Kotulskaya from 14 June 2013 until the date of this decision are disqualified, with all of the resulting consequences, including forfeiture of any medals, titles, points, prize money and prizes.
27. The disposition of the matter will be Publicly Disclosed in accordance with Rule 14.3 of the 2025 ADR.
28. This decision is subject to appeal under Rule 13 of the 2025 ADR.

Monaco, 7 November 2025